NextCure Corporation (NXTC): Aggregate Business Value

NextCure, Inc. (NXTC) is recognized as a pioneer in activating the body's own defenses against tumors, enjoying the trust of physicians and capital investors. NextCure, Inc. (NXTC) relies on extensive patents that ensure a multi-year monopoly and high profitability. The current portfolio is focused on early stages, which is offset by significant liquidity reserves. Enterprise Value stands at 10.36. This chart illustrates the price action, visualizing the market value of the business.

NXTC (NextCure, Inc.) Total Company Value history from 11/23/2025 to 10/28/2026

NextCure, Inc. - analytical breakdowns and key metrics (NXTC)

- price and consensus price forecast:

Share Price NextCure Inc|NXTC - Consensus Target

- market capitalization data:

Market Value NextCure|NXTC - Enterprise Value

- book capitalization data:

Accounting Value per Share NextCure|NXTC - Company Book Value|Market-to-Book Ratio nextcure.com|NXTC - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio NextCure, Inc.|NXTC - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio nextcure.com|NXTC - Company Debts|Debts to Book Value NextCure

Fundamental valuation:NextCure Inc (NXTC)

The vulnerability of NextCure, Inc. (NXTC) patents to market shocks necessitates strict control over its capital structure. The availability of liquid reserves for R&D temporarily offsets early-stage trial risks. This metric combines market capitalization with net debt, reflecting the total cost of acquiring control over the assets. Analyzing the real cost of business acquisition allows for the elimination of short-term stock volatility. It is critical for investors to weigh this total against the potential for future therapeutic breakthroughs.

Competitors of NextCure, Inc. (NXTC)

IBRX - Business Value|Real Price to Acquire Entire Company Immunocore PLC IMCR|JANX - Aggregate Business Value|RCUS (Arcus Biosciences, Inc.) - Enterprise Value|ZYME (zymeworks.com) - Real Price to Acquire Entire Company|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|IPHA: Total Enterprise Value|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IOBT (IO Biotech, Inc.)|Total Enterprise Value sutrobio.com|INKT: Enterprise Value|Full Takeover Company Value werewolftx.com HOWL|IMMX: Real Price to Acquire Entire Company|ALXO - Total Enterprise Value|Real Price to Acquire Entire Company Cue Biopharma, Inc. (CUE)|PDSB - Value Adjusted for Debt and Cash|sonnetbio.com - Enterprise Value|MAIA (MAIA Biotech) - Company Buyout Price|Total Company Value LIMN|Real Price to Acquire Entire Company LVTX|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)